Dana-Farber Cancer Institute | Strategic Alliance Partners

George D. Demetri, MD, discusses current trends in sarcoma care, how the field of sarcoma has paved the way for other tumor types, and emerging therapeutic advances in the field.

Kenneth Anderson, MD, PhD, discusses the role of APRIL/BCMA and what potential the targeted agent BION-1301 may have in blocking multiple myeloma cell proliferation, as well as reducing drug resistance and immunosuppression in the tumor microenvironment.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of cabozantinib as a second-line treatment of patients with renal cell carcinoma (RCC).

David P. Steensma, MD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute discusses myelodysplastic syndromes.

Toni Choueiri, MD, discusses the CheckMate-025 and METEOR trials and the potential for nivolumab and cabozantinib in the first- and second-line settings for treating renal cell carcinoma.

George D. Demetri, MD, whose teamwork approach has helped pave the way for new drugs for hard-to-treat sarcomas, was honored in the Gastrointestinal Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

David Reardon, MD, discusses the ReACT study and the potential of rindopepimut and other immunotherapy agents for the treatment of patients with brain cancers, specifically glioblastoma.

Jennifer R. Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses duvelisib for the treatment of chronic lymphocytic leukemia (CLL).

Kenneth C. Anderson, MD, has helped transform multiple myeloma from an essentially untreatable disease to a chronic condition. He was honored in the Myeloma category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group has launched to honor leaders in the field.

Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström's macroglobulinemia.

Jennifer R. Brown, MD, PhD, discusses the future of chronic lymphocytic leukemia treatment.

Dozens of genetic abnormalities, including 44 mutated genes and 11 recurrent somatic copy number variations, were found to potentially play a role in progression and/or relapse of chronic lymphocytic leukemia.

George D. Demetri, MD, expands on the challenges with overall survival as a primary outcome measure, the potential of trabectedin in soft tissue sarcomas, and the significance of a recent trial.

Limited clinical evaluation suggests a potentially major role for immune checkpoint inhibition in the treatment of lymphomas, but early success has also raised many questions.

Molecular profiling of every patient with acute myelogenous leukemia may hold the key to better treatment in the future.

Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma.

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

Research evidence has been mounting that PARP inhibitors are not just for gynecologic malignancies-or for patients whose tumors harbor inherited BRCA defects.

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.

Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses adding platinum-based therapy to the neoadjuvant setting for the treatment of patients with triple-negative breast cancer.

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

Although BRCA1/2 mutations have been intensely studied in breast cancer for more than a decade, researchers are still seeking to determine which patient populations should be screened for abnormalities and how best to integrate that information into treatment protocols.

Treatment with inotuzumab ozogamicin demonstrated a complete response (CR) or CR with incomplete platelet recovery rate of 80.7% in patients with relapsed or refractory acute lymphoblastic leukemia.

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.